Highlights of the 2026 European Crohn's and Colitis Conference: redefining the IBD care continuum.

IF 1.8 Q3 GASTROENTEROLOGY & HEPATOLOGY
Crohn's & Colitis 360 Pub Date : 2026-07-07 eCollection Date: 2026-07-01 DOI:10.1093/crocol/otag075
Ahmed Al-Hindawi, Alexander Siegel, Clive Jude Miranda, Gautam Maddineni, Mohammad Shehab
{"title":"Highlights of the 2026 European Crohn's and Colitis Conference: redefining the IBD care continuum.","authors":"Ahmed Al-Hindawi, Alexander Siegel, Clive Jude Miranda, Gautam Maddineni, Mohammad Shehab","doi":"10.1093/crocol/otag075","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction and purpose: </strong>Inflammatory bowel disease (IBD) care is moving from a symptom-driven step-up model of care toward earlier effective intervention, complication-specific management, and more personalized treatment selection. This review synthesizes selected ECCO 2026 studies and offers an expert appraisal of their clinical relevance, methodological strengths, and remaining uncertainties. Particular emphasis is placed on studies most likely to influence current practice and further research, including late-breaking trials, complication-directed therapy, pediatric evidence, and technology-assisted assessment.</p><p><strong>Summary of findings: </strong>Study findings spanned both ulcerative colitis (UC) and Crohn's disease (CD). New therapeutic studies presented included the phase 3 study of vedolizumab in pediatric UC, phase 2 efficacy data for picankibart in UC, and regenerative fistula data of AVB-114 in perianal CD. Real-world data presented included comparative data on different Janus kinase inhibitors in UC. Updates on interleukin-23 included durable extension data in UC, as well as efficacy data in advanced therapy‑exposed patients (mirikizumab in UC and risankizumab in CD). Innovative technologies included transperineal ultrasound for early identification of steroid non-response in acute severe UC, and multimodal artificial intelligence for Mayo endoscopic scoring. Beyond drug therapy, the 10-year LIR! C follow-up provided further data on surgical intervention as an early strategy in selected uncomplicated ileal CD, while the Preventing IBD ONset in Individuals at Risk study investigated potential benefits of a whole-food diet in high-risk first-degree relatives.</p><p><strong>Conclusion and next steps: </strong>ECCO 2026 emphasized durable, precision-oriented, multidisciplinary, and technology-enabled IBD care across the full continuum, from prevention to long-term modification. Apart from phase 3 and extension trials, other results remain preliminary and need broader comparative and practice-embedded studies before widespread adoption.</p>","PeriodicalId":10847,"journal":{"name":"Crohn's & Colitis 360","volume":"8 3","pages":"otag075"},"PeriodicalIF":1.8000,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13399156/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Crohn's & Colitis 360","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/crocol/otag075","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/7/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction and purpose: Inflammatory bowel disease (IBD) care is moving from a symptom-driven step-up model of care toward earlier effective intervention, complication-specific management, and more personalized treatment selection. This review synthesizes selected ECCO 2026 studies and offers an expert appraisal of their clinical relevance, methodological strengths, and remaining uncertainties. Particular emphasis is placed on studies most likely to influence current practice and further research, including late-breaking trials, complication-directed therapy, pediatric evidence, and technology-assisted assessment.

Summary of findings: Study findings spanned both ulcerative colitis (UC) and Crohn's disease (CD). New therapeutic studies presented included the phase 3 study of vedolizumab in pediatric UC, phase 2 efficacy data for picankibart in UC, and regenerative fistula data of AVB-114 in perianal CD. Real-world data presented included comparative data on different Janus kinase inhibitors in UC. Updates on interleukin-23 included durable extension data in UC, as well as efficacy data in advanced therapy‑exposed patients (mirikizumab in UC and risankizumab in CD). Innovative technologies included transperineal ultrasound for early identification of steroid non-response in acute severe UC, and multimodal artificial intelligence for Mayo endoscopic scoring. Beyond drug therapy, the 10-year LIR! C follow-up provided further data on surgical intervention as an early strategy in selected uncomplicated ileal CD, while the Preventing IBD ONset in Individuals at Risk study investigated potential benefits of a whole-food diet in high-risk first-degree relatives.

Conclusion and next steps: ECCO 2026 emphasized durable, precision-oriented, multidisciplinary, and technology-enabled IBD care across the full continuum, from prevention to long-term modification. Apart from phase 3 and extension trials, other results remain preliminary and need broader comparative and practice-embedded studies before widespread adoption.

2026年欧洲克罗恩病和结肠炎会议亮点:重新定义IBD护理连续性
简介和目的:炎症性肠病(IBD)的治疗正在从症状驱动型的渐进治疗模式转向早期有效干预、并发症特异性管理和更个性化的治疗选择。本综述综合了选定的ECCO 2026研究,并对其临床相关性、方法学优势和剩余的不确定性进行了专家评估。特别强调的是最有可能影响当前实践和进一步研究的研究,包括最新的试验、并发症导向治疗、儿科证据和技术辅助评估。研究结果总结:研究结果涵盖溃疡性结肠炎(UC)和克罗恩病(CD)。新的治疗研究包括vedolizumab治疗儿童UC的3期研究,picankibart治疗UC的2期疗效数据,AVB-114治疗肛周CD的再生瘘数据。实际数据包括不同Janus激酶抑制剂治疗UC的比较数据。白细胞介素-23的最新数据包括UC的持久扩展数据,以及晚期治疗暴露患者的疗效数据(mirikizumab用于UC和risankizumab用于CD)。创新技术包括用于早期识别急性重症UC中类固醇无反应的经会阴超声,以及用于Mayo内镜评分的多模式人工智能。除了药物治疗,10年LIR!C随访提供了手术干预作为选择的简单回肠CD的早期策略的进一步数据,而预防高危个体IBD发病的研究调查了全食物饮食对高危一级亲属的潜在益处。结论及后续措施:ECCO 2026强调从预防到长期治疗的整个连续体中持久、精确、多学科和技术支持的IBD护理。除了第三阶段和扩展试验,其他结果仍处于初步阶段,在广泛采用之前需要更广泛的比较和实践研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Crohn's & Colitis 360
Crohn's & Colitis 360 Medicine-Gastroenterology
CiteScore
2.50
自引率
0.00%
发文量
41
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书